Even small biotech companies are taking more control of their product development as cash, competition, and other factors combine to bolster their negotiating power.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barrett, A. Pfizer's Funk. Business Week, February 28, 2005, p. 72. http://www.businessweek.com/magazine/content/05_09/b3922001_mz001.htm
McKinnon, R. et al. Crisis? What Crisis? A Fresh Diagnosis of Big Pharma's R&D Productivity Crunch (Marakon Associates, NY, 2004). http://www.marakon.com/ideas_pdf/id_041104_mckinnon.pdf
Thiel, K. Goodbye, Columbus! New NRDOs forego discovery. Nat. Biotechnol. 22, 1087–1092 (2004).
Villiger, R. & Bogdan, B. Getting real about valuations in biotech. Nat. Biotechnol. 23, 423–428 (2005).
DiMasi, J.A. et al. The price of innovation: new estimates of drug development costs. J. Health Economics 22, 151–185 (2003).
Given, R., Snyder, G. & Wei, D. Critical Factors for Alliance Formation: Insights from the Deloitte Research Biotech Alliance Survey (Deloitte Research, New York, 2005). http://www.deloitte.com/dtt/cda/doc/content/DTT_DR_BIOTECH_June05Final(2).pdf
Roche, K. “Deal Statistics Quarterly,” In Vivo: The Business & Medicine Report, 23, 79 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiel, K. A very firm handshake: biotech's growing negotiating power. Nat Biotechnol 23, 1221–1226 (2005). https://doi.org/10.1038/nbt1005-1221
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1221
This article is cited by
-
Minimizing leakage of value from R&D alliances
Nature Reviews Drug Discovery (2007)
-
Shift toward early-stage deals favors biotechs
Nature Biotechnology (2006)
